Key Takeaways
- CDMO engine delivers 23% growth: The generic formulation CDMO vertical posted its largest-ever revenue quarter at ₹135.9 crores, driving overall revenue up 21% Y-o-Y to ₹175 crores, the sixth consecutive record quarter.
- Injectable facility costs arrive before revenue: Additional operating costs and depreciation from the new injectable business hit this quarter with zero revenue contribution, alongside a 25% minimum-wage increase in Uttarakhand, yet the company still delivered 12% EBITDA margin.
- European market authorizations signal export ambition: The company signed an agreement to acquire a basket of European MAs, a first step toward technology transfer into its own plants and a higher-margin export mix over the next 3–4 years.
- Capacity build-out targets ₹1,000 Cr readiness: Plant 2 expansion, a shortlisted acquisition target, and spare-floor optionality in the injectable facility are all being lined up so the company can serve ₹1,000 Cr revenue without capacity constraint by end-FY25.
- What to watch next quarter: Whether injectable revenue actually begins mid-Q3 as guided, the closing and price of the European MA acquisition, and any update on the shortlisted facility acquisition that management aims to complete by end-FY25.
CDMO Vertical: The Core Growth Engine
- Record quarter, structural drivers: The generic formulation CDMO vertical hit ₹135.9 crores in revenue, growing 23% Y-o-Y, driven by business-development team expansion, new product launches, wallet-share gains, and a broadening customer base.
- Quality regulation as a tailwind: New Schedule M rules make marketers equally responsible for manufacturing defects, pushing them toward better manufacturers, a shift management believes benefits Windlas directly.
- API prices are not the story: API prices are stable to declining for common molecules, yet CDMO grew 23% and trade generics 14%. The CDMO business is cost-plus, so unit realization moves marginally with input costs, but management stressed that growth and input-cost changes cannot be directly linked: the company grew even when API prices rose sharply.
- Volume growth in Indian pharma is negligible: The Indian pharma market grew just 0.7% YoY by volume, so CDMO growth is almost entirely a share-gain and execution story rather than a market tailwind.
Komal Gupta: "we don't want any vertical to be looked at on a quarter-to-quarter level because quarter-to-quarter variations will always remain because of various internal as well as external factors, but we are very excited, we are looking positive momentum there and it is not specific to this quarter. Now it is kind of becoming a habit for us and our investors to see."
Injectable Facility: Costs Now, Revenue Later
- Costs landed in Q1 with no offset: The injectable facility added manpower costs and depreciation on ~₹74–75 crores of plant and machinery (at ~18% WDV rate) this quarter, with no revenue contribution. Depreciation will decline over years as the written-down value decreases.
- Revenue timeline is mid-Q3, bulk in Q4: Commercial batches are being manufactured against orders and incubated for stability. The first sale is expected mid-Q3, and once a product is first sold, all batches manufactured for that product can be sold in a lump, so Q4 should see a larger revenue drop.
- ROCE will start low, improve with export mix: The injectable facility carries a lower asset turn (~1.2x) than the base OSD business. Management's plan is to use initial years to register dossiers in export markets; in 3–4 years, exports become the driver, changing the margin profile and ROCE materially for the better.
- Spare capacity is built in: A spare floor in the injectable facility allows capacity to be added quickly, with surrounding infrastructure already in place, so the company can expand before utilization becomes a constraint.
- Trade generics already seeding injectable demand: The company introduced injectable products in its trade generics division, sourced externally for now, to build the distribution network ahead of its own manufacturing coming online.
Hitesh Windlass: "the idea is to use the initial years to register more and more dossiers in our export markets and then in the later years as those registrations get approval, we'll be able to do a much higher profitability business through exports"
Margins: Absorbing Headwinds, Waiting for Revenue
- Two cost shocks absorbed: A near-25% increase in Uttarakhand minimum wages (unexpected, now the base going forward) and injectable-facility costs (manpower plus depreciation) hit simultaneously. Despite this, overall EBITDA came in at 12% and PBT at 10.5%.
- Existing business margins already improved: Management stated that the existing business improved its margins this quarter versus Q1 FY24, Q4 FY24, and full-year FY24, and that trajectory is continuing.
- ESOP charge now in the base: The ESOP 2023 scheme impact was absent in Q1 FY24 but is now a recurring cost, adding to the personnel-expense comparison.
- Margin recovery path is tied to injectable revenue: Management expects profitability margins to improve once injectable revenue begins, with the overall company-level revenue and margin both moving up.
Capacity & M&A: Building for ₹1,000 Cr
- Plant 2 expansion on a near-term clock: Expansion is in full swing and expected to be available by end of Q2 or beginning of Q3 FY25.
- A facility acquisition is in the pipeline: The company has identified and shortlisted a facility but has not yet reached documentation completion. The goal is to be ready with the additional facility by end-FY25 to deliver growth. An update is expected by end of next quarter.
- The ₹1,000 Cr capacity goal: Both the plant expansion and the new facility acquisition are aimed at ensuring the company can serve ₹1,000 Cr in revenue without any capacity constraint by end of this year.
- Dosage-form expansion is a strategic priority: Management is keen to expand into ointments, soft gels, hormones, steroids, eye drops, and protein powders to broaden the portfolio across CDMO, trade generics, and institutional verticals.
- M&A criteria are quality-first, not size-driven: The company is not targeting a specific size; the priority is asset quality, established customers, and quality standards at par with its own. Turnaround assets are off the table unless it is a complete slam dunk, because they consume too much management bandwidth.
Hitesh Windlass: "we are not targeting a size. For us, the idea is to add to the breadth of our business, which can serve all three verticals. So, the quality of the asset is the most important thing and how much can we grow if we acquire that asset"
Trade Generics, Institutional & Exports
- Trade generics and institutional grew 14% Y-o-Y: Revenue of ₹35.1 crores was driven by an expanded distribution network, new sales team members covering additional territory, more institutions, and more products.
- Quarterly variability is structural: Management cautioned against reading any single quarter, noting that the last eight quarters showed growth swings of 19%, 18%, and 73%, and the vertical should be viewed over a longer time span.
- Institutional margins vary by product: The company does not disclose the trade generics vs. institutional split for competitive reasons. As a basket, the aim is to maintain at least the material margin level between trade generics and CDMO.
- Jan Aushadhi expansion is a visible tailwind: The government plans to expand Jan Aushadhi Kendras from 8,000 to ~26,000 in the next 1.5 years, which management sees as a very big push in the government institutional space.
- Exports grew 10% Y-o-Y from a small base: Revenue was ₹4.1 crores. Management noted that exports grew ~30% in FY24 and that the segment is easier to expand from a particular base once reached, though no timeline was given.
European Market Authorizations: The Export Bridge
- A basket of European MAs was acquired: The company entered into an agreement to acquire market authorizations in Europe, expanding both its product portfolio and geographic reach. The cost was not disclosed.
- Three-step strategy: First, use the MAs to strengthen core markets; then execute technology transfer to bring products into Windlas's own plants, which will take some time; finally, explore opportunities in markets where its plants are already approved, including Europe and South Africa.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable revenue start | First revenue from sale of stability batches | Mid-Q3 FY25, bulk in Q4 FY25 |
| Plant 2 expansion availability | Additional capacity online | End of Q2 or beginning of Q3 FY25 |
| Capacity readiness for ₹1,000 Cr revenue | Plant expansion plus facility acquisition to remove capacity constraint | By end of FY25 |
| Facility acquisition update | Shortlisted facility, documentation not complete; update expected | By end of next quarter (Q2 FY25) |
| Margin improvement | Positive impact on profitability margins expected | Upon initiation of injectable revenue |
| Injectable facility export-driven ROCE improvement | Exports become the driver of profitability and ROCE | Next 3–4 years |
| Tax rate | More or less similar tax rate going forward | Ongoing |
| Balance sheet numbers (net cash, working capital) | Will be provided | By end of Q2 FY25 (September) |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹175 cr, +21% YoY |
| EBITDA | ₹21 cr, +22% YoY |
| EBITDA margin | 12%, overall; existing business margins improved YoY, QoQ, and vs full year FY24 |
| PBT | ₹18 cr, +12.1% YoY |
| PBT margin | 10.5% |
| EPS | ₹6.47, +12% YoY from ₹5.79 in Q1 FY24 |
| CDMO revenue | ₹135.9 cr, +23% YoY; largest ever quarter for the vertical |
| Trade generics & institutional revenue | ₹35.1 cr, +14% YoY |
| Exports revenue | ₹4.1 cr, +10% YoY |
| CDMO capacity utilization | ~65% (excluding injectable plant); peak utilization is 65–70% |
| Depreciation | ₹6 cr quarterly run rate, up from ₹3.5 cr; annual depreciation ~₹12 cr |
| Injectable facility revenue start | Mid-Q3 FY25 expected first revenue; commercial batches under stability testing |
| Injectable facility capex | ₹74–75 cr |
| Maintenance capex | ₹10–12 cr per year |